Yongtao Ji

Plain English
Researchers created a gel-like material that, when injected under the skin, converts immune cells called monocytes into more powerful dendritic cells that can recognize and attack cancer. The gel works by releasing chemicals that attract monocytes and then activates a specific pathway (DC-SIGN) that transforms them into the desired immune cells, which then train the body's T cells to fight tumors. When tested in mice and using human colorectal cancer samples, this approach stopped cancer growth and prevented tumors from coming back after surgery, suggesting it could be an effective new cancer treatment.

Plain English
Researchers found that pancreatic cancer cells produce high levels of lactate (a byproduct of metabolism), which chemically modifies proteins in tumor cells and makes the immune system unable to attack the cancer—explaining why immunotherapy often fails for pancreatic cancer patients. When they blocked lactate production or prevented this chemical modification, the immune system could recognize and kill cancer cells again, making immunotherapy work much better. This matters because it reveals a specific mechanism driving treatment resistance in pancreatic cancer and points to a new way to help immunotherapy succeed for patients who currently have few effective options.

Plain English
Researchers developed a step-by-step method to extract immune cells from pancreatic cancer tumors and identify different types of immune cells using a laboratory technique called flow cytometry. This extracted material can also be used for additional genetic analysis. This protocol helps scientists understand which immune cells are present in pancreatic cancer and how they behave, which could lead to better cancer treatments.

Plain English
Researchers studied pancreatic cancer tumors and discovered that a specific type of immune cell called proliferating resident macrophages actively helps cancer survive chemotherapy drugs by changing their metabolism—specifically by producing more of a molecule that blocks the cancer drug gemcitabine from entering cells. When scientists removed these problematic immune cells from mice with pancreatic cancer, the tumors became sensitive to chemotherapy again and the cancer spread less. This finding suggests that targeting these particular immune cells could make chemotherapy work better for pancreatic cancer patients.

Plain English
Pancreatic cancer is notoriously hard to treat because it surrounds itself with a protective barrier of fibroblast cells and immune-suppressing molecules that block standard therapies from working. Researchers discovered that blocking a protein called MFAP5 in these protective fibroblast cells weakens this barrier, allowing chemotherapy drugs and immunotherapy to penetrate the tumor and kill cancer cells more effectively. This finding matters because it offers a new combination therapy approach: targeting MFAP5 in the fibroblasts while simultaneously hitting the cancer cells with existing drugs could significantly improve survival rates for pancreatic cancer patients who currently have very poor outcomes.

Plain English
Researchers engineered cancer-fighting immune cells (CAR-T cells) using two techniques: adding extra copies of a gene called RUNX3 and treating the cells with a drug that blocks a protein called AKT. This combination created immune cells that stayed active longer, infiltrated tumors more effectively, and killed cancer cells better than standard CAR-T cells. The scientists tested these enhanced cells against pancreatic cancer in mice and found they not only worked powerfully on their own but also responded even better when combined with another cancer drug, suggesting this approach could overcome major obstacles in treating solid tumors with CAR-T cell therapy.

Plain English
Pancreatic cancer tumors create low-oxygen environments that weaken the immune system's ability to fight cancer, so researchers designed tiny oxygen-filled capsules to deliver oxygen directly into tumors and restore normal oxygen levels. When they combined these oxygen capsules with standard immunotherapy drugs in lab studies, the treatment worked much better—the oxygen reduced tumor-promoting immune cells and boosted cancer-fighting immune cells instead. This approach could become a new way to make immunotherapy more effective against pancreatic cancer.

Plain English
Tumors create oxygen-starved environments that make cancer worse by helping it spread, resist drugs, and hide from the immune system. Researchers are developing tiny nanoparticles that can fix this problem in four ways: by delivering oxygen directly to tumors, creating oxygen inside tumors, restructuring the tumor environment, or reducing how much oxygen cancer cells use up. This review examines all these approaches and explains how they could make cancer treatments more effective.

Plain English
Engineers built a portable defibrillator (a device that restarts a stopped heart) controlled by computer chips that can analyze heart rhythms, deliver electrical shocks when needed, and store patient data for later review. The device displays information on a screen and gives voice instructions to guide the person using it. The team specifically designed an efficient electrical discharge system and programmed the device to work reliably in real emergency situations.